支架市场机会、成长要素、产业趋势分析及2026-2035年预测。

预计到 2025 年，全球支架市场价值将达到 101 亿美元，并预计以 8.4% 的复合年增长率成长，到 2035 年达到 223 亿美元。

市场成长的驱动因素包括心血管疾病盛行率上升、微创手术的日益普及、支架设计技术的进步以及新兴地区医疗基础设施的扩建。支架是一种小型管状医疗设备，能够维持狭窄或阻塞血管的通畅性，确保血流稳定并防止血管闭塞。冠状动脉疾病、周边动脉疾病和动脉瘤发生率的不断上升，以及久坐不动的生活方式、不良饮食和吸烟等不良习惯，共同推动了支架治疗的需求。药物释放型支架、生物可吸收支架和生物可降解聚合物涂层等技术创新正在改善患者预后、降低再狭窄血管再阻塞并提高手术安全性。此外，以患者为中心的解决方案、与数位医疗的融合以及智慧支架的研发也促进了市场发展，从而拓展了治疗选择，并提高了全球范围内的支架应用。

预计到2025年，血管支架市占率将达到93%，这主要得益于冠状动脉疾病盛行率的上升以及对微创心血管治疗需求的成长。与开胸搭桥手术相比，血管内支架置入术术因其恢復时间更短、併发症风险更低、住院时间更短而更受欢迎。心血管护理中心的扩建、技术娴熟的专家团队的增多以及人们对早期检测意识的提高，尤其是在亚太地区、拉丁美洲和中东地区，都促进了血管支架的广泛应用。

预计到2025年，医院市场将占据73.6%的市场份额，达到160亿美元。由于支架植入可以缩短恢復时间、降低手术风险并提高病患处理效率，医院越来越多地进行经皮冠状动脉介入治疗和血管内手术。人口老化和生活方式相关风​​险因素导致心血管疾病患者数量不断增加，从而推动了心臟和周边血管介入治疗中支架需求的增长。

预计到2025年，美国支架市场规模将达35亿美元。冠状动脉和周边动脉疾病盛行率的不断上升，以及与老化、肥胖、高血压和糖尿病相关的风险因素，正在推动文明病的成长。先进的医疗设施、专业的心臟中心和导管检查室的普及，使得支架植入术得以高频进行。此外，美国和加拿大的保险覆盖范围和报销政策也鼓励患者接受择期手术和急诊手术，进一步促进了市场成长。

目录

第一章：调查方法

• 研究途径
• 品质改进计划
  • GMI人工智慧政策和资料完整性倡议
    • 资讯来源一致性通讯协定
• 调查过程和可靠性评分
  • 调查过程的组成部分
  • 评分组成部分
• 数据收集
  • 主要来源部分列表
• 资料探勘资讯来源
  • 付费资讯来源
    • 区域资讯来源
• 基本估算和计算方法
  • 每种方法中基准年的计算
• 预测模型
  • 量化市场影响分析
    • 生长参数对预测的数学影响
• 关于调查透明度的补充信息
  • 资讯来源归属框架
  • 品质保证指标
  • 对信任的承诺

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 心血管疾病盛行率增加
    • 支架技术的进步
    • 微创手术增加
    • 提高对早期诊断和治疗的认识
  • 产业潜在风险与挑战
    • 支架治疗高成本
    • 併发症和血管再阻塞的风险
  • 市场机会
    • 生物可吸收支架和下一代支架的研发
    • 在诊断领域不断扩大数位医疗和人工智慧的应用
• 成长潜力分析
• 监理情势（基于初步调查）
  • 北美洲
  • 欧洲
  • 亚太地区
• 科技趋势
  • 当前技术趋势
  • 新兴技术
• 还款方案（基于初步调查）
• 未来市场趋势
• 价值链分析
• 消费者洞察（基于初步研究）
• 波特五力分析
• PESTEL 分析
• 差距分析

第四章 竞争情势

• 介绍
• 企业矩阵分析
• 企业市占率分析（基于初步研究）
  • 世界
  • 北美洲
  • 欧洲
  • 亚太地区
• 竞争定位矩阵
• 主要市场公司的竞争分析
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估价与预测：依产品划分，2022-2035年

• 血管支架
  • 冠状动脉支架
    • 药物释放型支架
    • 生物可吸收血管支架（BVS）
    • 裸金属支架
  • 外周支架
    • 肾
    • 髂骨
    • 股腘窝
    • 颈动脉
  • 神经血管支架
• 非血管支架

第六章 市场估计与预测：依材料划分，2022-2035年

• 金属
• 聚合物

第七章 市场估计与预测：依类型划分，2022-2035年

• 球囊扩张型
• 自膨胀

第八章 市场估算与预测：依最终用途划分，2022-2035年

• 医院
• 门诊手术中心
• 其他最终用户

第九章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十章：公司简介

• Abbott
• B. Braun
• Becton, Dickinson and Company
• Biosensors International Group
• Biotronik
• Boston Scientific
• Elixir Medical
• Medtronic
• Meril Life Science
• MicroPort Scientific
• SLTL Group
• Stryker
• Terumo
• Veryan Medical
• WL Gore &Associates

The Global Stents Market was valued at USD 10.1 billion in 2025 and is estimated to grow at a CAGR of 8.4% to reach USD 22.3 billion by 2035.

Market growth is driven by the rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive procedures, technological advancements in stent design, and expanding healthcare infrastructure in emerging regions. Stents are small, tubular medical devices that maintain the patency of narrowed or blocked blood vessels, ensuring consistent blood flow and preventing vessel collapse. The growing incidence of coronary artery disease, peripheral artery disease, and aneurysms, combined with lifestyle factors such as sedentary behavior, poor diet, and smoking, fuels demand for stent procedures. Innovations, including drug-eluting stents, bioresorbable stents, and biodegradable polymer coatings, enhance patient outcomes, reduce restenosis, and improve procedural safety. The market is further propelled by patient-centric solutions, digital health integration, and the development of smart stents, which collectively expand treatment options and adoption globally.

The vascular stents segment held a share of 93% in 2025, driven by the widespread prevalence of coronary artery disease and preference for minimally invasive cardiovascular interventions. Endovascular stenting is favored over open surgical bypass due to shorter recovery times, lower complication risks, and reduced hospital stays. Expansion of cardiovascular care centers, availability of trained specialists, and growing awareness of early detection, particularly in Asia-Pacific, Latin America, and the Middle East, contribute to increasing adoption of vascular stents.

The hospitals segment accounted for 73.6% share in 2025, reaching USD 16 billion. Hospitals are increasingly performing percutaneous coronary interventions and endovascular procedures, as stent implantation shortens recovery periods, reduces procedural risks, and improves patient throughput. The rising number of patients with cardiovascular conditions due to aging populations and lifestyle-related risk factors is driving higher demand for stents in both cardiac and peripheral interventions.

U.S. Stents Market reached USD 3.5 billion in 2025. The increasing prevalence of coronary artery disease and peripheral artery disease, combined with aging demographics and lifestyle-related risks such as obesity, hypertension, and diabetes, drives procedural volumes. The presence of advanced hospitals, specialized cardiac centers, and catheterization labs facilitates high-volume stent implantation. Insurance coverage and reimbursement policies in the U.S. and Canada also encourage patients to undergo both elective and emergency procedures, further supporting market growth.

Prominent players in the Global Stents Market include Abbott, Medtronic, Boston Scientific, Biotronik, MicroPort Scientific, Stryker, W.L Gore & Associates, B. Braun, Biosensors International Group, Terumo, Veryan Medical, Elixir Medical, Johnson & Johnson, and SLTL Group. Companies in the Global Stents Market strengthen their presence by focusing on continuous research and development to improve stent design, durability, and safety features. They are expanding production capacities, forming strategic partnerships with hospitals and healthcare providers, and entering emerging markets to reach underserved populations. Firms emphasize minimally invasive and patient-specific solutions, integrate digital health technologies with smart stents, and launch drug-eluting and bioresorbable products to enhance clinical outcomes. Marketing initiatives, training programs for clinicians, and collaborations with key cardiovascular centers help companies build brand trust, drive adoption, and maintain a competitive edge in the global market.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Material trends
  • 2.2.4 Type trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Advancements in stent technology
    • 3.2.1.3 Increasing number of minimally invasive procedures
    • 3.2.1.4 Growing awareness about early diagnosis and treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of stent procedures
    • 3.2.2.2 Risk of complications and restenosis
  • 3.2.3 Market opportunities
    • 3.2.3.1 Development of bioresorbable and next-gen stents
    • 3.2.3.2 Increasing adoption of digital health and AI in diagnostics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Reimbursement scenario (Driven by primary research)
• 3.7 Future market trends
• 3.8 Value chain analysis
• 3.9 Consumer insights (Driven by primary research)
• 3.10 Porter's analysis
• 3.11 PESTEL analysis
• 3.12 Gap analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by primary research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Vascular stents
  • 5.2.1 Coronary stents
    • 5.2.1.1 Drug eluting stent
    • 5.2.1.2 Bioresorbable vascular scaffold (BVS)
    • 5.2.1.3 Bare metal stent
  • 5.2.2 Peripheral stents
    • 5.2.2.1 Renal
    • 5.2.2.2 Iliac
    • 5.2.2.3 Femoral-popliteal
    • 5.2.2.4 Carotid
  • 5.2.3 Neurovascular stents
• 5.3 Non-vascular stents

Chapter 6 Market Estimates and Forecast, By Material, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Metal
• 6.3 Polymer

Chapter 7 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Balloon expandable
• 7.3 Self expandable

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory surgical centers
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott
• 10.2 B. Braun
• 10.3 Becton, Dickinson and Company
• 10.4 Biosensors International Group
• 10.5 Biotronik
• 10.6 Boston Scientific
• 10.7 Elixir Medical
• 10.8 Medtronic
• 10.9 Meril Life Science
• 10.10 MicroPort Scientific
• 10.11 SLTL Group
• 10.12 Stryker
• 10.13 Terumo
• 10.14 Veryan Medical
• 10.15 W.L Gore & Associates